Brief: FDA Accepts Kala Pharmaceuticals' IND Application for KPI-012

KALA BIO

27/12/2022 21:57

Dec 27 (Reuters) - Kala Pharmaceuticals Inc  KALA.O :
    * KALA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF IND
APPLICATION
FOR KPI-012 FOR THE TREATMENT OF PCED
    * KALA PHARMACEUTICALS INC - ON-TRACK TO INITIATE PHASE 2B
TRIAL
IN 1Q 2023; TOPLINE DATA EXPECTED IN 1Q 2024
    * KALA PHARMACEUTICALS INC - RECEIVED REMAINING $25 MILLION
INVESTMENT UNDER PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT
FINANCING

Source text for Eikon:  ID:nGNX9C5znQ 
Further company coverage:  KALA.O 
 ((Reuters.Briefs@thomsonreuters.com;))